Surprisingly, mathematical modeling of these variations revealed that MAPK signaling negative feedback via IGF-1R reactivated MAPK signaling to mediate cancer cell drug resistance, highlighting the concomitant targeting of MEK and IGF-1R/MAPK signaling pathways as a potential therapeutic strategy in high-risk neuroblastoma. This evidence concerns the gene IGF1R and neuroblastoma.